Human immunodeficiency virus 1

Summary

Alias: human immunodeficiency virus 1 HIV-1, human immunodeficiency virus-1 HIV-1, human immunodeficiency virus type-1 HIV-1, human immunodeficiency virus type I HIV-1, human immunodeficiency virus type 1, HIV-1, human immunodeficiency virus type 1 HIV1, human immunodeficiency virus type 1 HIV-1, human immunodeficiency virus type 1 HIV 1, human immunodeficiency virus HIV-1, Human immunodeficiency virus type 1, HIV-1, LAV-1, HIV1, HIV, human immunodeficiency virus type 1 ,HIV-1, Human immunodeficiencey virus type 1, Human immundeficiency virus type 1, AIDS virus

Top Publications

  1. doi Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
    Stuart J D Neil
    Aaron Diamond AIDS Research Center and Laboratory of Retrovirology, The Rockefeller University, 455 First Avenue, New York, New York 10016, USA
    Nature 451:425-30. 2008
  2. doi Genome-scale RNAi screen for host factors required for HIV replication
    Honglin Zhou
    Department of Virus and Cell Biology, Merck and Co, Inc, West Point, PA 19486, USA
    Cell Host Microbe 4:495-504. 2008
  3. pmc Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication
    Renate König
    Infectious and Inflammatory Disease Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Cell 135:49-60. 2008
  4. pmc Crystal structure of a soluble cleaved HIV-1 envelope trimer
    Jean Philippe Julien
    Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Science 342:1477-83. 2013
  5. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
  6. pmc The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein
    Nanette Van Damme
    The San Diego Department of Veterans Affairs Healthcare System, San Diego, CA 92161, USA
    Cell Host Microbe 3:245-52. 2008
  7. pmc Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer
    Dmitry Lyumkis
    National Resource for Automated Molecular Microscopy, The Scripps Research Institute, La Jolla, CA 92037, USA
    Science 342:1484-90. 2013
  8. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
  9. pmc Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein
    Kasia Hrecka
    Department of Molecular Biology and Microbiology, Case School of Medicine, Cleveland, Ohio 44106, USA
    Nature 474:658-61. 2011
  10. pmc HIV-1 evades innate immune recognition through specific cofactor recruitment
    Jane Rasaiyaah
    University College London, Medical Research Council Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 90 Gower Street, London WC1E 6BT, UK
    Nature 503:402-5. 2013

Research Grants

  1. MOLECULAR MECHANISM OF TAT INDUCED ANGIOGENESIS
    Cindy Morris; Fiscal Year: 2002
  2. HIV vectors for stem cell and intrakine gene delivery
    Richard Sutton; Fiscal Year: 2004
  3. Ziwei Huang; Fiscal Year: 2016
  4. The Role of Lipid Rafts in Vpu Function
    EDWARD BRICE STEPHENS; Fiscal Year: 2011
  5. Transcriptional Regulation and Expression of Human APOBEC3G
    SUSANNE BOBADILLA; Fiscal Year: 2011
  6. MICHAEL A BELSHAN; Fiscal Year: 2014
  7. Harris A Gelbard; Fiscal Year: 2014
  8. CORECEPTOR USAGE AND HIV DISEASE KINETICS
    Donald Mosier; Fiscal Year: 1999
  9. Heterogeneity in Cytokine Responses to HIV-1 Infection
    Jianming Tang; Fiscal Year: 2011
  10. HIV/TB in Uganda: Punctuated Antiretroviral Therapy
    Christopher Whalen; Fiscal Year: 2007

Patents

  1. PRIME-BOOST REGIMENS WITH A TLR4 AGONIST ADJUVANT AND A LENTIVIRAL VECTOR
  2. Mitochondrial Proteins Constructs and Uses Thereof
  3. RNA amplification and iagnostic method of HIV-1 infection
  4. Conditionally Immortalized Long-Term Stem Cells and Methods of Making and Using Such Cells
  5. A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW& AND HIGH MOLECULAR WEIGHT COMPOUNDS
  6. METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION
  7. Genome editing for the treatment of huntington's disease
  8. PATHOGENIC CONTROL OF APOPTOSIS
  9. Well-tolerated and highly specific tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains
  10. METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION

Detail Information

Publications379 found, 100 shown here

  1. doi Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
    Stuart J D Neil
    Aaron Diamond AIDS Research Center and Laboratory of Retrovirology, The Rockefeller University, 455 First Avenue, New York, New York 10016, USA
    Nature 451:425-30. 2008
    ..that inhibits the release of retrovirus particles, and other enveloped virus particles, and is antagonized by the HIV-1 accessory protein, Vpu...
  2. doi Genome-scale RNAi screen for host factors required for HIV replication
    Honglin Zhou
    Department of Virus and Cell Biology, Merck and Co, Inc, West Point, PA 19486, USA
    Cell Host Microbe 4:495-504. 2008
    Human immunodeficiency virus (HIV)-1 depends on the host cell machinery to support its replication...
  3. pmc Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication
    Renate König
    Infectious and Inflammatory Disease Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Cell 135:49-60. 2008
    Human Immunodeficiency Viruses (HIV-1 and HIV-2) rely upon host-encoded proteins to facilitate their replication...
  4. pmc Crystal structure of a soluble cleaved HIV-1 envelope trimer
    Jean Philippe Julien
    Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Science 342:1477-83. 2013
    b>HIV-1 entry into CD4(+) target cells is mediated by cleaved envelope glycoprotein (Env) trimers that have been challenging to characterize structurally. Here, we describe the crystal structure at 4...
  5. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
    ..Nab) are a principal component of an effective human immune response to many pathogens, yet their role in HIV-1 infection is unclear...
  6. pmc The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein
    Nanette Van Damme
    The San Diego Department of Veterans Affairs Healthcare System, San Diego, CA 92161, USA
    Cell Host Microbe 3:245-52. 2008
    The HIV-1 accessory protein Vpu counteracts a host factor that restricts virion release from infected cells. Here we show that the interferon-induced cellular protein BST-2/HM1.24/CD317 is such a factor...
  7. pmc Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer
    Dmitry Lyumkis
    National Resource for Automated Molecular Microscopy, The Scripps Research Institute, La Jolla, CA 92037, USA
    Science 342:1484-90. 2013
    The HIV-1 envelope glycoprotein (Env) trimer contains the receptor binding sites and membrane fusion machinery that introduce the viral genome into the host cell...
  8. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
    Cross-reactive neutralizing antibodies (NAbs) are found in the sera of many HIV-1-infected individuals, but the virologic basis of their neutralization remains poorly understood...
  9. pmc Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein
    Kasia Hrecka
    Department of Molecular Biology and Microbiology, Case School of Medicine, Cleveland, Ohio 44106, USA
    Nature 474:658-61. 2011
    ..b>Human immunodeficiency virus 1 (HIV-1) fails to transduce dendritic cells and has a reduced ability to transduce macrophages, due to ..
  10. pmc HIV-1 evades innate immune recognition through specific cofactor recruitment
    Jane Rasaiyaah
    University College London, Medical Research Council Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 90 Gower Street, London WC1E 6BT, UK
    Nature 503:402-5. 2013
    Human immunodeficiency virus (HIV)-1 is able to replicate in primary human macrophages without stimulating innate immunity despite reverse transcription of genomic RNA into double-stranded DNA, an activity that might be expected to ..
  11. pmc Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection
    Caroline Goujon
    Department of Infectious Diseases, King s College London, London SE1 9RT, UK
    Nature 502:559-62. 2013
    ..For the pathogenic retrovirus human immunodeficiency virus type 1 (HIV-1), these include widely expressed restriction factors, such as APOBEC3 proteins, TRIM5-α, ..
  12. pmc Tetherin inhibits HIV-1 release by directly tethering virions to cells
    David Perez-Caballero
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    Cell 139:499-511. 2009
    Tetherin is an interferon-induced protein whose expression blocks the release of HIV-1 and other enveloped viral particles...
  13. pmc Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
    Dan H Barouch
    1 Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA 2 Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts 02139, USA
    Nature 503:224-8. 2013
    b>Human immunodeficiency virus type 1 (HIV-1)-specific monoclonal antibodies with extraordinary potency and breadth have recently been described...
  14. pmc SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates
    Hichem Lahouassa
    Institut National de la Santé et de la Recherche Médicale U1016, Institut Cochin, Paris, France
    Nat Immunol 13:223-8. 2012
    SAMHD1 restricts the infection of dendritic and other myeloid cells by human immunodeficiency virus type 1 (HIV-1), but in lentiviruses of the simian immunodeficiency virus of sooty mangabey (SIVsm)-HIV-2 lineage, SAMHD1 is counteracted ..
  15. pmc Structure of a V3-containing HIV-1 gp120 core
    Chih Chin Huang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    Science 310:1025-8. 2005
    The third variable region (V3) of the HIV-1 gp120 envelope glycoprotein is immunodominant and contains features essential for coreceptor binding...
  16. pmc Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains
    Daniel Sauter
    Institute of Molecular Virology, Universitatsklinikum, 89081 Ulm, Germany
    Cell Host Microbe 6:409-21. 2009
    Vpu proteins of pandemic HIV-1 M strains degrade the viral receptor CD4 and antagonize human tetherin to promote viral release and replication...
  17. pmc HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP
    Bijan Sobhian
    Laboratoire de Virologie Moleculaire, Institut de Genetique Humaine, CNRS UPR1142, Montpellier, France
    Mol Cell 38:439-51. 2010
    b>HIV-1 transactivator Tat has greatly contributed to our understanding of transcription elongation by RNAPII. We purified HIV-1 Tat-associated factors from HeLa nuclear extract and show that Tat forms two distinct and stable complexes...
  18. pmc Structural definition of a conserved neutralization epitope on HIV-1 gp120
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 445:732-7. 2007
    The remarkable diversity, glycosylation and conformational flexibility of the human immunodeficiency virus type 1 (HIV-1) envelope (Env), including substantial rearrangement of the gp120 glycoprotein upon binding the CD4 receptor, allow ..
  19. pmc Molecular architecture of native HIV-1 gp120 trimers
    Jun Liu
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Nature 455:109-13. 2008
    The envelope glycoproteins (Env) of human and simian immunodeficiency viruses (HIV and SIV, respectively) mediate virus binding to the cell surface receptor CD4 on target cells to initiate infection...
  20. pmc A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies
    Rogier W Sanders
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, United States of America Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    PLoS Pathog 9:e1003618. 2013
    A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1) vaccine candidate is the ability to induce broadly neutralizing antibodies (bNAbs)...
  21. pmc MX2 is an interferon-induced inhibitor of HIV-1 infection
    Melissa Kane
    1 Aaron Diamond AIDS Research Center, New York, New York 10016, USA 2 Laboratory of Retrovirology, The Rockefeller University, New York, New York 10065, USA
    Nature 502:563-6. 2013
    b>HIV-1 replication can be inhibited by type I interferon (IFN), and the expression of a number of gene products with anti-HIV-1 activity is induced by type I IFN...
  22. ncbi The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys
    Matthew Stremlau
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 427:848-53. 2004
    ..b>Human immunodeficiency virus type 1 (HIV-1), the cause of acquired immunodeficiency syndrome (AIDS) in humans, efficiently enters the ..
  23. pmc Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism
    Janet L Douglas
    Oregon Health and Science University, Vaccine and Gene Therapy Institute, Beaverton, 97006, USA
    J Virol 83:7931-47. 2009
    The primary roles attributed to the human immunodeficiency virus type 1 (HIV-1) Vpu protein are the degradation of the viral receptor CD4 and the enhancement of virion release...
  24. pmc APOBEC proteins and intrinsic resistance to HIV-1 infection
    Michael H Malim
    Department of Infectious Diseases, King s College London School of Medicine, 2nd Floor, Borough Wing, Guy s Hospital, London Bridge, London SE1 9RT, UK
    Philos Trans R Soc Lond B Biol Sci 364:675-87. 2009
    ..family of cellular polynucleotide cytidine deaminases, most notably APOBEC3G and APOBEC3F, are potent inhibitors of HIV-1 infection...
  25. pmc Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Science 329:811-7. 2010
    During HIV-1 infection, antibodies are generated against the region of the viral gp120 envelope glycoprotein that binds CD4, the primary receptor for HIV-1...
  26. pmc TRIM5 is an innate immune sensor for the retrovirus capsid lattice
    Thomas Pertel
    Department of Microbiology and Molecular Medicine, University of Geneva, Geneva CH 1211, Switzerland
    Nature 472:361-5. 2011
    TRIM5 is a RING domain-E3 ubiquitin ligase that restricts infection by human immunodeficiency virus (HIV)-1 and other retroviruses immediately following virus invasion of the target cell cytoplasm...
  27. pmc SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx
    Nadine Laguette
    Institut de Genetique Humaine, Laboratoire de Virologie Moleculaire, CNRS UPR1142, Montpellier 34000, France
    Nature 474:654-7. 2011
    ..Vpx counteracts an unknown restriction factor that renders human dendritic and myeloid cells largely refractory to HIV-1 infection. Here we identify SAMHD1 as this restriction factor...
  28. pmc HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription
    Nanhai He
    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA
    Mol Cell 38:428-38. 2010
    Recruitment of the P-TEFb kinase by HIV-1 Tat to the viral promoter triggers the phosphorylation and escape of RNA polymerase II from promoter-proximal pausing...
  29. pmc Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure
    Tommi A White
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, United States of America
    PLoS Pathog 6:e1001249. 2010
    The initial step in target cell infection by human, and the closely related simian immunodeficiency viruses (HIV and SIV, respectively) occurs with the binding of trimeric envelope glycoproteins (Env), composed of heterodimers of the ..
  30. doi HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor
    Christine Goffinet
    Department of Virology, University of Heidelberg, Heidelberg, Germany
    Cell Host Microbe 5:285-97. 2009
    ..Human CD317 (BST-2/HM1.24/tetherin) is a restriction factor that blocks release of human immunodeficiency virus type 1 (HIV-1) from the cell surface and can be overcome by HIV-1 Vpu...
  31. doi The interferon-inducible MxB protein inhibits HIV-1 infection
    Zhenlong Liu
    Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
    Cell Host Microbe 14:398-410. 2013
    ..We find that human MxB inhibits HIV-1 infection by reducing the level of integrated viral DNA...
  32. pmc Nucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity
    Kenneth A Matreyek
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Pathog 9:e1003693. 2013
    ..showed that the viral capsid (CA) protein mediated the dependency on cellular nucleoporin (NUP) 153 during HIV-1 infection, and now demonstrate a direct interaction between the CA N-terminal domain and the phenylalanine-..
  33. doi The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells
    Xavier Lahaye
    Institut Curie, 12 rue Lhomond, 75005 Paris, France INSERM U932, 12 rue Lhomond, 75005 Paris, France
    Immunity 39:1132-42. 2013
    b>HIV-2 is less pathogenic for humans than HIV-1 and might provide partial cross-protection from HIV-1-induced pathology...
  34. ncbi The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells
    G B Cohen
    Department of Biology, Massachusetts Institute of Technology, Cambridge 02139, USA
    Immunity 10:661-71. 1999
    To avoid detection by CTL, HIV encodes mechanisms for removal of class I MHC proteins from the surface of infected cells. However, class I downregulation potentially exposes the virus-infected cell to attack by NK cells...
  35. doi HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells
    James Arthos
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Immunol 9:301-9. 2008
    Infection with human immunodeficiency virus 1 (HIV-1) results in the dissemination of virus to gut-associated lymphoid tissue...
  36. pmc Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4
    Chih Chin Huang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 317:1930-4. 2007
    The CCR5 co-receptor binds to the HIV-1 gp120 envelope glycoprotein and facilitates HIV-1 entry into cells. Its N terminus is tyrosine-sulfated, as are many antibodies that react with the co-receptor binding site on gp120...
  37. pmc Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120
    Lei Chen
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 326:1123-7. 2009
    The site on HIV-1 gp120 that binds to the CD4 receptor is vulnerable to antibodies. However, most antibodies that interact with this site cannot neutralize HIV-1...
  38. pmc BST-2/tetherin: a new component of the innate immune response to enveloped viruses
    David T Evans
    Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center, One Pine Hill Drives, Southborough, MA 01772, USA
    Trends Microbiol 18:388-96. 2010
    ..This barrier was crossed by HIV-1 when its Vpu protein acquired activity as a BST-2 antagonist...
  39. pmc Analysis of the interaction of primate retroviruses with the human RNA interference machinery
    Jennifer Lin
    Center for Virology, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 81:12218-26. 2007
    The question of whether retroviruses, including human immunodeficiency virus type 1 (HIV-1), interact with the cellular RNA interference machinery has been controversial...
  40. doi Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses
    Frank Kirchhoff
    Institute of Molecular Virology, University Hospital Ulm, Meyerhofstrasse 1, 89081 Ulm, Germany
    Cell Host Microbe 8:55-67. 2010
    ..In addition, primate lentiviruses, such as HIV-1, have acquired several "accessory" genes that antagonize antiviral host restriction factors and facilitate viral ..
  41. pmc Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9
    Jean Philippe Julien
    Department of Integrative Structural and Computational Biology, International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 110:4351-6. 2013
    PG9 is the founder member of an expanding family of glycan-dependent human antibodies that preferentially bind the HIV (HIV-1) envelope (Env) glycoprotein (gp) trimer and broadly neutralize the virus. Here, we show that a soluble SOSIP...
  42. pmc Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
    Masashi Shingai
    1 Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA 2
    Nature 503:277-80. 2013
    ..However, earlier studies of anti-human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies administered to infected individuals or humanized mice reported ..
  43. pmc Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity
    Xiaojun Wang
    Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan 48824 4320, USA
    J Virol 85:3142-52. 2011
    ..A3H) has one cytidine deaminase domain (CDD) and inhibits the replication of retrotransposons and human immunodeficiency virus type 1 (HIV-1) in a Vif-resistant manner...
  44. pmc Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus
    Alberto De Iaco
    Department of Microbiology and Molecular Medicine, University of Geneva, 1 rue Michel Servet, CH 1211 Geneva, Switzerland
    Retrovirology 8:98. 2011
    b>HIV-1 infects non-dividing cells. This implies that the virus traverses the nuclear pore before it integrates into chromosomal DNA. Recent studies demonstrated that TNPO3 is required for full infectivity of HIV-1...
  45. pmc Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    James M Binley
    IMM2, Department of Immunology, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
    J Virol 78:13232-52. 2004
    Broadly neutralizing monoclonal antibodies (MAbs) are potentially important tools in human immunodeficiency virus type 1 (HIV-1) vaccine design...
  46. ncbi DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
    T B Geijtenbeek
    Department of Tumor Immunology, University Medical Center St Radboud, Nijmegen, The Netherlands
    Cell 100:587-97. 2000
    ..of a DC-specific C-type lectin, DC-SIGN, that is highly expressed on DC present in mucosal tissues and binds to the HIV-1 envelope glycoprotein gp120...
  47. pmc APOBEC3G inhibits elongation of HIV-1 reverse transcripts
    Kate N Bishop
    Department of Infectious Diseases, King s College London School of Medicine, Guy s Hospital, London, United Kingdom
    PLoS Pathog 4:e1000231. 2008
    APOBEC3G (A3G) is a host cytidine deaminase that, in the absence of Vif, restricts HIV-1 replication and reduces the amount of viral DNA that accumulates in cells...
  48. pmc Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin
    Sheli R Radoshitzky
    U S Army Medical Research Institute of Infectious Diseases, 1425 Porter St, Fort Detrick, Frederick, MD 21702, USA
    J Virol 84:10569-80. 2010
    Bone marrow stromal antigen 2 (BST-2/tetherin) is a cellular membrane protein that inhibits the release of HIV-1...
  49. pmc Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells
    Clare Jolly
    MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, Windeyer Building, London, United Kingdom
    J Virol 84:12185-99. 2010
    Direct cell-to-cell spread of human immunodeficiency virus type 1 (HIV-1) between T cells at the virological synapse (VS) is an efficient mechanism of viral dissemination...
  50. pmc Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1
    Judd F Hultquist
    Department of Biochemistry, Molecular Biology and Biophysics, Institute for Molecular Virology, Center for Genome Engineering, University of Minnesota, Minneapolis, MN 55455, USA
    J Virol 85:11220-34. 2011
    ..For example, to replicate efficiently in CD4(+) T lymphocytes, human immunodeficiency virus type 1 (HIV-1) encodes a protein called viral infectivity factor (Vif) that promotes pathogenesis by ..
  51. pmc HIV-1 assembly, budding, and maturation
    Wesley I Sundquist
    Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, Utah, USA
    Cold Spring Harb Perspect Med 2:a006924. 2012
    ..Here, we review our current understanding of the mechanisms of HIV-1 assembly, budding, and maturation, starting with a general overview and then providing detailed descriptions of ..
  52. pmc TNPO3 protects HIV-1 replication from CPSF6-mediated capsid stabilization in the host cell cytoplasm
    Alberto De Iaco
    Department of Microbiology and Molecular Medicine, University of Geneva, 1205, Geneva, Switzerland
    Retrovirology 10:20. 2013
    Despite intensive investigation the mechanism by which HIV-1 reaches the host cell nucleus is unknown. TNPO3, a karyopherin mediating nuclear entry of SR-proteins, was shown to be required for HIV-1 infectivity...
  53. pmc Rational HIV immunogen design to target specific germline B cell receptors
    Joseph Jardine
    Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
    Science 340:711-6. 2013
    Vaccine development to induce broadly neutralizing antibodies (bNAbs) against HIV-1 is a global health priority...
  54. doi HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration
    Arik Cooper
    Virology Laboratory, Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    Nature 498:376-9. 2013
    Human immunodeficiency virus-1 (HIV-1) has infected more than 60 million people and caused nearly 30 million deaths worldwide, ultimately the consequence of cytolytic infection of CD4(+) T cells...
  55. ncbi Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B
    J Luban
    Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, New York 10032
    Cell 73:1067-78. 1993
    ..identified two host proteins, cyclophillins (CyPs) A and B, which interact specifically with the human immunodeficiency virus type 1 (HIV-1) Gag polyprotein Pr55gag...
  56. doi Transportin-SR2 imports HIV into the nucleus
    Frauke Christ
    Laboratory for Molecular Virology and Gene Therapy, KU Leuven and IRC, Kapucijnenvoer 33, B 3000 Leuven, Flanders, Belgium
    Curr Biol 18:1192-202. 2008
    The human immunodeficiency virus type 1 (HIV-1) and other lentiviruses have the capacity to infect nondividing cells like macrophages. This requires import of the preintegration complex (PIC) through the nuclear pore...
  57. pmc Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility
    Tomoko Kobayashi
    Laboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto University, 53 Shogoin Kawahara cho, Sakyo ku, Kyoto 606 8507, Japan
    J Virol 85:932-45. 2011
    Tetherin, also known as BST-2/CD317/HM1.24, is an antiviral cellular protein that inhibits the release of HIV-1 particles from infected cells...
  58. pmc HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes
    Yukie Iwabu
    Department of Pathology, National Institute of Infectious Diseases, Tokyo 162 8640, Japan
    J Biol Chem 284:35060-72. 2009
    ..This antiviral effect is counteracted by the human immunodeficiency virus type 1 (HIV-1) accessory protein viral protein U (Vpu)...
  59. pmc Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation
    Rajesh P Ringe
    Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10065
    Proc Natl Acad Sci U S A 110:18256-61. 2013
    ..uncleaved envelope glycoprotein (Env gp)140 trimers from the subtype A HIV type 1 (HIV-1) strain BG505...
  60. pmc Increasing the potency and breadth of an HIV antibody by using structure-based rational design
    Ron Diskin
    Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA
    Science 334:1289-93. 2011
    Antibodies against the CD4 binding site (CD4bs) on the HIV-1 spike protein gp120 can show exceptional potency and breadth. We determined structures of NIH45-46, a more potent clonal variant of VRC01, alone and bound to gp120...
  61. doi Structural basis for hijacking CBF-β and CUL5 E3 ligase complex by HIV-1 Vif
    Yingying Guo
    1 School of Life Science and Technology, Harbin Institute of Technology, Harbin 150080, China 2
    Nature 505:229-33. 2014
    The human immunodeficiency virus (HIV)-1 protein Vif has a central role in the neutralization of host innate defences by hijacking cellular proteasomal degradation pathways to subvert the antiviral activity of host restriction factors; ..
  62. pmc Distribution of ESCRT machinery at HIV assembly sites reveals virus scaffolding of ESCRT subunits
    Schuyler B Van Engelenburg
    Cell Biology and Metabolism Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD 20892, USA
    Science 343:653-6. 2014
    The human immunodeficiency virus (HIV) hijacks the endosomal sorting complexes required for transport (ESCRT) to mediate virus release from infected cells...
  63. ncbi Specific incorporation of cyclophilin A into HIV-1 virions
    E K Franke
    Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, New York 10032
    Nature 372:359-62. 1994
    ..We have previously shown that the principal structural protein of the human immunodeficiency virus HIV-1, the Gag polyprotein, binds the cyclophilin peptidyl-prolyl isomerases; cyclophilins catalyse a rate-limiting ..
  64. pmc Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment
    Mathieu Dubé
    Laboratory of Human Retrovirology, Institut de recherches cliniques de Montreal IRCM, Montreal, Quebec, Canada
    PLoS Pathog 6:e1000856. 2010
    The Vpu accessory protein promotes HIV-1 release by counteracting Tetherin/BST-2, an interferon-regulated restriction factor, which retains virions at the cell-surface...
  65. pmc Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu
    Andrey A Tokarev
    Department of Medicine University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0679, USA
    J Virol 85:51-63. 2011
    The HIV-1 protein Vpu counteracts the antiviral activity of the innate restriction factor BST-2/tetherin by a mechanism that partly depends on its interaction with β-TrCP, a substrate adaptor for an SCF (Skp-Cullin 1-F box) E3 ubiquitin ..
  66. ncbi A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA
    P Wei
    Regulatory Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, California 92037 1099, USA
    Cell 92:451-62. 1998
    The HIV-1 Tat protein regulates transcription elongation through binding to the viral TAR RNA stem-loop structure...
  67. pmc LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration
    Ming Chieh Shun
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Division of AIDS, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genes Dev 21:1767-78. 2007
    ..A novel genetic knockout model was established that allowed us for the first time to analyze HIV-1 integration in the absence of LEDGF/p75 protein...
  68. pmc Flexible use of nuclear import pathways by HIV-1
    Kyeongeun Lee
    HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702, USA
    Cell Host Microbe 7:221-33. 2010
    b>HIV-1 replication requires transport of nascent viral DNA and associated virion proteins, the retroviral preintegration complex (PIC), into the nucleus...
  69. pmc Broad neutralization coverage of HIV by multiple highly potent antibodies
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California 92037, USA
    Nature 477:466-70. 2011
    ..Here we probed the neutralizing antibody repertoires of four human immunodeficiency virus (HIV)-infected donors with remarkably broad and potent neutralizing responses and rescued 17 new monoclonal antibodies ..
  70. pmc Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities
    Luis J Cocka
    Department of Microbiology, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania, USA
    PLoS Pathog 8:e1002931. 2012
    ..s-Tetherin), which lacks 12 residues present in the long isoform (l-Tetherin), is significantly more resistant to HIV-1 Vpu-mediated downregulation and consequently more effectively restricts HIV-1 viral budding in the presence of ..
  71. pmc Stimulation of NF-κB activity by the HIV restriction factor BST2
    Andrey Tokarev
    The University of California San Diego, La Jolla California, USA
    J Virol 87:2046-57. 2013
    ..is an interferon-inducible transmembrane protein that restricts the release of several enveloped viruses, including HIV, from infected cells...
  72. pmc BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism
    Daniela Boehm
    Gladstone Institute of Virology and Immunology, San Francisco, CA, USA
    Cell Cycle 12:452-62. 2013
    ..We find that BET inhibitor compounds (JQ1, I-Bet, I-Bet151 and MS417) reactivate HIV from latency...
  73. pmc The requirement for nucleoporin NUP153 during human immunodeficiency virus type 1 infection is determined by the viral capsid
    Kenneth A Matreyek
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, 450 Brookline Avenue, CLS 1010, Boston, MA 02215, USA
    J Virol 85:7818-27. 2011
    ..TNPO3) and NPC component nucleoporin 153 (NUP153) as being important for infection by human immunodeficiency virus type 1 (HIV-1)...
  74. ncbi Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes
    J M Escola
    Department of Cell Biology, Utrecht University School of Medicine, AZU, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    J Biol Chem 273:20121-7. 1998
    ....
  75. pmc Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin
    Nolwenn Jouvenet
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York, USA
    J Virol 83:1837-44. 2009
    ..protein, termed tetherin (previously known as BST-2 or CD317), blocks the release of nascent human immunodeficiency virus type 1 (HIV-1) particles from infected cells, and an HIV-1 accessory protein, Vpu, acts as a viral ..
  76. pmc Tetherin restricts direct cell-to-cell infection of HIV-1
    Björn D Kuhl
    McGill University AIDS Center, Lady Davis Institute, Jewish General Hospital, Montreal, Canada
    Retrovirology 7:115. 2010
    ..interferon (IFN)-inducible factor of the innate immune system, recently shown to exert antiviral activity against HIV-1 and other enveloped viruses by tethering nascent viral particles to the cell surface, thereby inhibiting viral ..
  77. pmc Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking
    Richard S Mitchell
    Department of Medicine, University of California San Diego, La Jolla, CA, USA
    PLoS Pathog 5:e1000450. 2009
    ..The HIV-1 accessory protein Vpu antagonizes this restriction by an unknown mechanism that likely involves the down-..
  78. pmc Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    Brandon F Keele
    Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
    Proc Natl Acad Sci U S A 105:7552-7. 2008
    The precise identification of the HIV-1 envelope glycoprotein (Env) responsible for productive clinical infection could be instrumental in elucidating the molecular basis of HIV-1 transmission and in designing effective vaccines...
  79. ncbi HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress
    J Martin-Serrano
    Aaron Diamond AIDS Research Center and The Rockefeller University, New York, New York, USA
    Nat Med 7:1313-9. 2001
    ..that interactions between Tsg101, a factor involved in endosomal protein sorting, and short peptide motifs in the HIV-1 Gag late domain and Ebola virus matrix (EbVp40) proteins are essential for efficient egress of HIV-1 virions and ..
  80. pmc Evidence for an activation domain at the amino terminus of simian immunodeficiency virus Vpx
    Thomas Gramberg
    New York University School of Medicine, Microbiology Department, 522 First Ave, New York, NY 10016, USA
    J Virol 84:1387-96. 2010
    ..Here, we confirm the ability of Vpx to enhance simian immunodeficiency virus (SIV) and human immunodeficiency virus type 1 (HIV-1) infection of macrophages up to 100-fold by using single-cycle reporter viruses and by ..
  81. pmc Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
    Nicole A Doria-Rose
    1 Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA 2
    Nature 509:55-62. 2014
    Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the HIV-1 envelope, but the mechanism of their elicitation has been unclear...
  82. pmc The molecular basis of HIV entry
    Per Johan Klasse
    Department of Microbiology and Immunology, Cornell University, Weill Cornell Medical College, 1300 York Avenue, Box 62, New York, NY 10065 4896, USA
    Cell Microbiol 14:1183-92. 2012
    Infection by HIV starts when the virus attaches to a susceptible cell...
  83. pmc Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans
    Jean Philippe Julien
    Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA
    PLoS Pathog 9:e1003342. 2013
    New broad and potent neutralizing HIV-1 antibodies have recently been described that are largely dependent on the gp120 N332 glycan for Env recognition...
  84. pmc An unusual topological structure of the HIV-1 Rev response element
    Xianyang Fang
    Protein Nucleic Acid Interaction Section, Structural Biophysics Laboratory, HIV Drug Resistance Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
    Cell 155:594-605. 2013
    Nuclear export of unspliced and singly spliced viral mRNA is a critical step in the HIV life cycle...
  85. pmc AFF1 is a ubiquitous P-TEFb partner to enable Tat extraction of P-TEFb from 7SK snRNP and formation of SECs for HIV transactivation
    Huasong Lu
    School of Pharmaceutical Sciences, Innovation Center for Cell Biology, Xiamen University, Xiamen 361005, Fujian, China
    Proc Natl Acad Sci U S A 111:E15-24. 2014
    ..and the bromodomain protein 4 (Brd4)-P-TEFb complex] that constitute a P-TEFb network controlling cellular and HIV transcription...
  86. pmc Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign
    Karen Tran
    International AIDS Vaccine Initiative Neutralizing Antibody Center, Departments of Integrative Structural and Computational Biology and Immunology and Microbial Science, and Center for HIV AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037
    Proc Natl Acad Sci U S A 111:E738-47. 2014
    b>HIV-1 neutralization requires Ab accessibility to the functional envelope glycoprotein (Env) spike...
  87. pmc TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements
    Anna Kajaste-Rudnitski
    Viral Pathogens and Biosafety Unit, Division of Immunology, Transplantation, and Infectious Diseases, San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy
    J Virol 85:5183-96. 2011
    ..clones of the U937 promonocytic cell line that were either permissive or nonpermissive for human immunodeficiency virus type 1 (HIV-1) replication...
  88. pmc Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120
    Ralph Pantophlet
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:642-58. 2003
    Alanine scanning mutagenesis was performed on monomeric gp120 of human immunodeficiency virus type 1 to systematically identify residues important for gp120 recognition by neutralizing and nonneutralizing monoclonal antibodies (MAbs) to ..
  89. ncbi HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites
    Peter D Kwong
    Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 420:678-82. 2002
    The ability of human immunodeficiency virus (HIV-1) to persist and cause AIDS is dependent on its avoidance of antibody-mediated neutralization...
  90. pmc Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells
    Theodora Hatziioannou
    Aaron Diamond AIDS Research Center and Rockefeller University, New York, New York 10021, USA
    J Virol 79:176-83. 2005
    Cyclophilin A (CypA) is a peptidyl-prolyl isomerase that binds to the capsid protein (CA) of human immunodeficiency virus type 1 (HIV-1) and by doing so facilitates HIV-1 replication...
  91. pmc Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription
    Dwayne A Bisgrove
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA 94158, USA
    Proc Natl Acad Sci U S A 104:13690-5. 2007
    ..Overexpression of the BRD4 P-TEFb-interacting domain disrupts the interaction between the HIV transactivator Tat and P-TEFb and suppresses the ability of Tat to transactivate the HIV promoter...
  92. pmc Imaging the biogenesis of individual HIV-1 virions in live cells
    Nolwenn Jouvenet
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10065, USA
    Nature 454:236-40. 2008
    ..We studied fluorescently tagged derivatives of Gag, the major structural component of HIV-1-which is sufficient to drive the assembly of virus-like particles-with the use of fluorescence resonance energy ..
  93. pmc Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses
    Efrem S Lim
    Division of Human Biology, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, P O Box 10924, Seattle, WA 98109 1024, USA
    J Virol 84:7124-34. 2010
    ..immunodeficiency viruses SIVcpz and SIVgor are able to antagonize their hosts' Tetherin with Nef, human immunodeficiency virus type 1 (HIV-1) Vpu has evolved to counteract Tetherin in humans...
  94. pmc Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions
    Victor Buzon
    Unit of Virus Host Cell Interactions UMI 3265, Université Joseph Fourier EMBL CNRS, Grenoble, France
    PLoS Pathog 6:e1000880. 2010
    The HIV-1 envelope glycoprotein (Env) composed of the receptor binding domain gp120 and the fusion protein subunit gp41 catalyzes virus entry and is a major target for therapeutic intervention and for neutralizing antibodies...
  95. pmc Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens
    Katie J Doores
    Department of Immunology and Microbial Science and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 107:13800-5. 2010
    The envelope spike of HIV is one of the most highly N-glycosylated structures found in nature...
  96. pmc HIV-1 Gag extension: conformational changes require simultaneous interaction with membrane and nucleic acid
    Siddhartha A K Datta
    HIV Drug Resistance Program, National Cancer Institute, PO Box B, Building 535, Fredrick, MD 21702 1201, USA
    J Mol Biol 406:205-14. 2011
    ..Through small-angle scattering and molecular modeling, we have previously shown that monomeric human immunodeficiency virus type 1 (HIV-1) Gag protein in solution adopts compact conformations...
  97. pmc HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction
    Sarah Schmidt
    Department of Infectious Diseases, Virology, University of Heidelberg, Heidelberg, Germany
    MBio 2:e00036-11. 2011
    The intrinsic immunity factor CD317 (BST-2/HM1.24/tetherin) imposes a barrier to HIV-1 release at the cell surface that can be overcome by the viral protein Vpu...
  98. pmc The role of cellular factors in promoting HIV budding
    Eric R Weiss
    Program in Gene Function and Expression, University of Massachusetts Medical School, Worcester, MA 01605, USA
    J Mol Biol 410:525-33. 2011
    b>Human immunodeficiency virus type 1 (HIV-1) becomes enveloped while budding through the plasma membrane, and the release of nascent virions requires a membrane fission event that separates the viral envelope from the cell surface...
  99. pmc Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity
    Emilie Battivelli
    INSERM U941, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    J Virol 85:11846-54. 2011
    Although laboratory-adapted HIV-1 strains are largely resistant to the human restriction factor TRIM5α (hTRIM5α), we have recently shown that some viruses carrying capsid (CA) sequences from clinical isolates can be more sensitive to ..
  100. pmc Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions
    Andres Finzi
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Department of Pathology, Division of AIDS, Harvard Medical School, Boston, MA 02115, USA
    Mol Cell 37:656-67. 2010
    The entry of human immunodeficiency virus (HIV-1) into cells is initiated by binding of the gp120 exterior envelope glycoprotein to the receptor, CD4...
  101. ncbi HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
    Y Feng
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases NIAID, NIH, Bethesda, MD 20892, USA
    Science 272:872-7. 1996
    A cofactor for HIV-1 (human immunodeficiency virus-type 1) fusion and entry was identified with the use of a novel functional complementary DNA (cDNA) cloning strategy...

Research Grants73

  1. MOLECULAR MECHANISM OF TAT INDUCED ANGIOGENESIS
    Cindy Morris; Fiscal Year: 2002
    DESCRIPTION (Adapted from the applicant's description) Human immunodeficiency virus type-1 (HIV-1)Tat is a potent transcriptional transactivator of both viral and cellular gene expression that possesses angiogenic properties...
  2. HIV vectors for stem cell and intrakine gene delivery
    Richard Sutton; Fiscal Year: 2004
    b>Human immunodeficiency virus type 1 (HIV) is the causative agent of the acquired immunodeficiency syndrome, or ADS. WHO estimates that, by the end of this year, 0.7 percent of the world's population will be infected with HIV...
  3. Ziwei Huang; Fiscal Year: 2016
    ..particularly CXCR4 that is one of two principal coreceptors required for the cellular entry of human immunodeficiency virus type 1 (HIV-1)...
  4. The Role of Lipid Rafts in Vpu Function
    EDWARD BRICE STEPHENS; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): Human immunodeficiency virus type 1 (HIV-1) encodes for a small type I membrane protein known as Vpu and has two major functions in the infected cell...
  5. Transcriptional Regulation and Expression of Human APOBEC3G
    SUSANNE BOBADILLA; Fiscal Year: 2011
    ..The project will investigate the transcriptional regulation of the gene that encodes the human immunodeficiency virus type 1 (HIV-1) restriction factor Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (..
  6. MICHAEL A BELSHAN; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): Drug resistant strains of human immunodeficiency virus type 1 (HIV-1) pose a significant challenge for effective long-term treatment of infection...
  7. Harris A Gelbard; Fiscal Year: 2014
    ..produced from cellular membranes in immune cells and neurons, in the disease state caused by human immunodeficiency virus type 1 (HIV-1) infection in the brain...
  8. CORECEPTOR USAGE AND HIV DISEASE KINETICS
    Donald Mosier; Fiscal Year: 1999
    This proposal deals with the relative efficiency of co-receptor utilization for human immunodeficiency virus-type 1 (HIV-1) to enter and infect different target cells...
  9. Heterogeneity in Cytokine Responses to HIV-1 Infection
    Jianming Tang; Fiscal Year: 2011
    ..provided by applicant): Immunological and clinical manifestations of natural and treated human immunodeficiency virus type 1 (HIV-1) Infection can vary considerably at the individual or population level...
  10. HIV/TB in Uganda: Punctuated Antiretroviral Therapy
    Christopher Whalen; Fiscal Year: 2007
    Tuberculosis (TB) is a common and serious complication of human immunodeficiency virus-type 1 (HIV) infection in the developing world, especially in sub-Saharan Africa...
  11. Recruitment of host noncoding RNAs by XMRV
    Sandra L Wolin; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Two human retroviruses, human immunodeficiency virus type 1 (HIV-1), the cause of acquired immune deficiency syndrome, and human T-cell leukemia virus type 1 (HTLV-1), which causes adult T-cell ..
  12. Actions of Vif and APOBEC3 proteins in HIV-1 Replication
    Yong Hui Zheng; Fiscal Year: 2010
    b>Human Immunodeficiency Virus Type 1 (HIV-1) infects CD4-positive T cells and monocytes/macrophages and cause Acquired Immune Deficiency Syndrome (AIDS) in humans...
  13. Marylyn D Ritchie; Fiscal Year: 2016
    ..However, there is considerable interindividual variability in response to human immunodeficiency virus type 1 (HIV-1) therapy regarding both efficacy and toxicity...
  14. Role of nucleic acid structure in HIV-1 replication
    Chandravanu Dash; Fiscal Year: 2011
    Acquired immunodeficiency syndrome (AIDS), caused by human immunodeficiency virus type 1 (HlV-1) is one of the most important challenges for chemotherapy of the early 21 st century...
  15. INHIBITION OF HIV 1 REPLICATION BY CYTOTOXIC LYMPHOCYTES
    Bruce D Walker; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Human immunodeficiency virus type 1 (HIV-1) is the cause of acquired immuno-deficiency syndrome (AIDS), and has already resulted in an ..
  16. Characterization of Nef vesicles and their effect on T cells and macrophage
    Michael D Powell; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Infection with Human Immunodeficiency Virus type 1 (HIV-1) results in dysregulation and the ultimate depletion of the immune system known as Acquired Immunodeficiency Syndrome (AIDS)...
  17. HIV Proteomic Center for Host-Viral Response Characterization
    Richard D Smith; Fiscal Year: 2010
    ..Project 1: To use high-throughput proteomics to define changes in the cerebrospinal fluid (CSF) proteome in HIV infection related to brain injury, intrathecal immune activation, CNS infection, and opioid use...
  18. Generating SEVI disaggregases to prevent HIV infection
    James Shorter; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Human immunodeficiency virus type-1 (HIV-1), the causative agent of acquired immune deficiency syndrome (AIDS), has infected ~60 million people worldwide and caused over 25 million deaths...
  19. Thomas B Campbell; Fiscal Year: 2016
    ..an integrative, multidisciplinary training program that provides basic, translational and clinical human immunodeficiency virus type 1 (HIV) Acquired Immunodeficiency Syndrome (AIDS)-related postdoctoral training under the direction ..
  20. DAVID MARSHALL GUIDOT; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): Project Abstract Chronic infection with human immunodeficiency virus type 1 (HIV-1) has emerged in the past 25 years as one of the greatest health challenges our society has ever faced...
  21. Pharmacology of Antiretroviral Nanoparticle Micelles
    Christopher J Destache; Fiscal Year: 2010
    ..therapy (HAART) has significantly diminished the mortality associated with human immunodeficiency virus type-1 (HIV-1) disease...
  22. Sharilyn Almodovar; Fiscal Year: 2014
    ..of viral replication and evolution in the lungs of patients infected with Human Immunodeficiency Virus type-1 (HIV-1) remain poorly understood...
  23. The Vaginal Microbiome: Disease, Genetics and the Environment
    GREGORY ALLEN BUCK; Fiscal Year: 2012
    ..in the vaginal microbiome may increase the likelihood of transmission of certain agents including human immunodeficiency virus type 1 (HIV-1). There are physiologic alterations in host condition (e.g...
  24. HIV-1 regulation by MTb: pathogen and host factor
    Anne Goldfeld; Fiscal Year: 2010
    ..that over 15% of annual tuberculosis (TB) cases occur in individuals who are co-infected with human immunodeficiency virus type 1 (HIV-1), and that TB has caused one-third to one-half of all AIDS deaths to date...
  25. Brian Wigdahl; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): Pathogenesis and disease progression subsequent to human immunodeficiency virus type 1 (HIV-1) infection of the immune system, brain, and other end organs is dependent on viral entry and replication ..
  26. Cellular and molecular mechanisms of gp120 neurotoxicity
    Italo Mocchetti; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Axonal injury is seen in subjects with Human Immunodeficiency Virus type 1 (HIV) associated dementia (HAD)...
  27. Vitamin D Inhibition of HIV and M. Tuberculosis Coinfection in Macrophages
    Stephen A Spector; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Human Immunodeficiency Virus type-1 (HIV) and Mycobacterium tuberculosis (Mtb) are among the leading causes of death worldwide with coinfection associated with increased mortality and greater ..
  28. Recombinase Polymerase Amplification for Point-of-Care Diagnosis of Infant HIV-1
    DAVID SCOTT BOYLE; Fiscal Year: 2013
    ..DESCRIPTION (provided by applicant): Over 50% of infants in sub-Saharan Africa who are infected with human immunodeficiency virus type 1 (HIV-1) die before 2 years of age...
  29. Improving Antibodies to Virion Based HIV Vaccines
    Kathie Grovit-Ferbas; Fiscal Year: 2013
    Emerging pathogens such as human immunodeficiency virus type 1 (HIV-1) are of central importance to VA Medical Centers across the United States...
  30. Modeling monocyte and macrophage based gene therapy for neuroAIDS
    Yuanan Lu; Fiscal Year: 2013
    Project Summary/Abstract Human immunodeficiency virus type 1 (HIV) infects brain macrophages and microglia and causes HIV- associated dementia (HAD), a primary disorder of the central nervous system (CNS) that affects about 20% of HIV-..
  31. Brent E Palmer; Fiscal Year: 2016
    ..has been recognized as one of the main targets of infectious and non-infectious complications of human immunodeficiency virus type 1 (HIV-1) infection...
  32. A Novel CNS-Penetrable Antiretroviral
    Ned C Sacktor; Fiscal Year: 2011
    ..of highly active antiretroviral therapy (HAART) in the mid-1990's for treatment of human immunodeficiency virus type 1 (HIV-1) infection, overall incidence rates of associated neurological maladies have declined...
  33. A New Insight into HIV-1 Latency Through a Novel in Vitro System
    Fabio Romerio; Fiscal Year: 2010
    ..applicant): A major challenge facing the AIDS field is the eradication of the human immunodeficiency virus type-1 (HIV-1)...
  34. Anna Moszczynska; Fiscal Year: 2016
    ..TAT is a domain of the human immunodeficiency virus type 1 that rapidly crosses the blood brain barrier...
  35. SETH MICHAEL DEVER; Fiscal Year: 2014
    ..splice variants other than the canonical MOR-1 might differentially regulate human immunodeficiency virus type-1 (HIV-1) pathogenesis in the central nervous system (CNS), or elsewhere, has been largely ignored...
  36. Carol A Carter; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): The human immunodeficiency virus type 1 (HIV) is the causative agent of the AIDS pandemic...
  37. Mario Stevenson; Fiscal Year: 2016
    ..The human immunodeficiency virus type 1 (HlV-1), the causative agent of AIDS, is a complex retrovirus that encodes six regulatory proteins, ..
  38. MLK3 inhibition protects the murine CNS from the effects of HIV-1 Tat
    Daniel F Marker; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Human immunodeficiency virus type 1 (HIV-1) enters the central nervous system (CNS) early in the course of infection, where it can persist in resident microglia and astrocytes(1, 2)...
  39. JOSE ORLANDO MALDONADO-ORTIZ; Fiscal Year: 2016
    ..Approximately 30 million individuals have died of AIDS and 33 million are currently infected with human immunodeficiency virus type 1 (HIV-1) worldwide...
  40. Immuno-Neuropathogenic mechanisms of HIV-1 clade B and C Infection
    Samikkannu Thangavel; Fiscal Year: 2013
    ..3 million people are infected with human immunodeficiency virus type-1 (HIV-1)...
  41. Jonathan Lai; Fiscal Year: 2014
    ..Monoclonal antibodies directed against the envelope glycoproteins of membrane viruses such as human immunodeficiency virus type 1 (HIV-1), influenza, and ebolavirus are essential reagents for deciphering mechanisms of viral entry,..
  42. Alterations in Lung Microbiome in Acute and Chronic HIV infection
    Andrew P Fontenot; Fiscal Year: 2013
    ..has been recognized as one of the main targets of infectious and non-infectious complications of human Immunodeficiency virus type 1 (HIV-1) infection...
  43. Monitoring single conformational events during HIV assembly
    WALTHER H MOTHES; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The human immunodeficiency virus type 1 (HIV) is the etiological agent of AIDS...
  44. MICHELLE MEGAN KIEBALA; Fiscal Year: 2014
    ..by applicant): The increased incidence of thrombotic complications in human immunodeficiency virus type-1 (HIV) infected populations, despite adequate control of the virus with combination antiretroviral therapy (cART), ..
  45. Biochemical Mechanisms of Drug Resistance in HIV RT
    Yanbin Zhang; Fiscal Year: 2012
    ..reverse transcriptase (RT) inhibitors continue to be an important component of therapy against human immunodeficiency virus type 1 (HIV-1)...
  46. MOJGAN HOSSEINI NAGHAVI; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Human immunodeficiency virus type 1 (HIV-1) is a member of the retroviridae that causes Acquired Immunodeficiency Syndome (AIDS), which affects over 33.3 million people worldwide...
  47. Benjamin K Chen; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): Efforts to develop an human immunodeficiency virus type 1 (HIV-1) vaccine that generate neutralizing antibodies have focused on antibodies that block cell-free viral transmission, yet it is ..
  48. A Cambodian Clinical Research Network for HIV &TB
    Sok Thim; Fiscal Year: 2011
    ..Of the estimated 42 million human immunodeficiency virus type 1 (HIV-1)-infected individuals globally, over 11 million are also co-infected with Mycobacterium ..
  49. Cellular Protein Involved in Trafficking of HIV-1
    Carol A Carter; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): The human immunodeficiency virus type 1 (HIV) is the causative agent of the AIDS pandemic...
  50. Joseph B Margolick; Fiscal Year: 2016
    ..by NIAID and NCI in 1983 to study the natural history of infection with human immunodeficiency virus, type 1 (HIV)...
  51. KATHARINE JUNE BAR; Fiscal Year: 2015
    DESCRIPTION (provided by applicant): The virus population bottleneck to Hepatitis C Virus (HCV) and Human Immunodeficiency Virus type 1 (HIV-1) transmission in injection drug users (IDUs) remains an understudied and controversial area ..
  52. Structure and Function of Ribonucleoprotein Complexes Modulating HIV Replication
    TARIQ RANA; Fiscal Year: 2009
    ..and function of complex assemblies involved in transcriptional activation of human immunodeficiency virus type-1 (HIV-1) gene expression...
  53. Structure and Function of Ribonucleoprotein Complexes Modulating HIV Replication
    Tariq M Rana; Fiscal Year: 2013
    ..and function of complex assemblies involved in transcriptional activation of human immunodeficiency virus type-1 (HIV-1) gene expression...
  54. The Semen Enhancer of HIV Infection as a Novel Microbicide Target
    Stephen Dewhurst; Fiscal Year: 2012
    ..contains cationic amyloid fibrils, termed the "Semen Enhancer of Virus Infection" (SEVI), which strongly enhance HIV-1 infection and may play an important role in viral transmission...
  55. A Novel Approach to Identify HIV Suppression Factor from CD8 Cells
    Phalguni Gupta; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): CD8+ T cells have been shown to suppress transcription of human immunodeficiency virus type 1 (HIV-1) in a MHC-unrestricted non-cytolytic manner...
  56. Interaction of Alcohol with HIV-Protein
    Norman J Haughey; Fiscal Year: 2011
    Human immunodeficiency virus type -1 (HIV-1) infection is the commonest cause of dementia in adults less than 40 years of age...
  57. Baek Kim; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Human immunodeficiency virus type 1 (HIV-1) uniquely infects both dividing/activated CD4+ T cell and nondividing cells such as macrophages...
  58. VIVIANA A SIMON; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): Human T-lymphotropic virus type I (HTLV-1) and Human Immunodeficiency virus type 1 (HIV-1) are the most common retroviruses found in humans...
  59. Krishanu Ray; Fiscal Year: 2014
    ..in applying advanced fluorescence spectroscopy techniques to interrogate virus-host interactions in early stages of HIV infection. Specifically, Dr...
  60. MULTI-DIMENSIONAL NMR OF HIV-1 ENVELOPE GLYCOPROTEINS
    Jacob Anglister; Fiscal Year: 2010
    The long term goals of our research are to learn about the mechanism for HIV-1 target recognition, to understand the selectivity of the virus to different cells of the immune system and to study mechanisms of viral entry inhibition...
  61. Mechanisms of Frailty in HIV-1 Infection
    Kristine Mace Erlandson; Fiscal Year: 2012
    ..The prevalence of frailty is 3-fold higher in human immunodeficiency virus type-1 (HIV-1) infected patients than age-matched HIV-negative controls, and occurs 20 years earlier than would be expected in ..
  62. Newcastle disease virus vectored HIV vaccines
    Siba K Samal; Fiscal Year: 2013
    ..The long range goal of our research is to develop an effective vaccine against human immunodeficiency virus type-1 (HIV-1) infection. We plan to use avian paramyxoviruses (APMVs) as vectors for delivery of HIV-1 proteins...
  63. MATHIAS LOESCHE; Fiscal Year: 2015
    ..retroviral polyprotein Gag is the essential factor in a large number of viral pathogens, such as human immunodeficiency virus type 1 (HIV-1) and oncoviruses, that promotes the budding of progeny viral shells after binding to the ..
  64. The Vaginal Microbiome: Disease, Genetics and the Environment
    Gregory Buck; Fiscal Year: 2009
    ..in the vaginal microbiome may increase the likelihood of transmission of certain agents including human immunodeficiency virus type 1 (HIV-1). There are physiologic alterations in host condition (e.g...
  65. Transcriptional Gene Silencing of HIV and CCR5
    Kevin Morris; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Human immunodeficiency virus type 1 (HIV-1) has been infecting humans for ~20 years now with little hope for an efficacious vaccine in the near future (Ho 2002)...
  66. Single and multi-component biguanide-based microbicides
    Mohamed Labib; Fiscal Year: 2006
    DESCRIPTION (provided by applicant): The quasi species nature of a human immunodeficiency virus type 1 (HIV-1) infection coupled with the virus's ability to rapidly mutate away from selective drug pressure has led to the use of ..
  67. Single and multi-component biguanide-based microbicides
    Mohamed Labib; Fiscal Year: 2007
    DESCRIPTION (provided by applicant): The quasi species nature of a human immunodeficiency virus type 1 (HIV-1) infection coupled with the virus's ability to rapidly mutate away from selective drug pressure has led to the use of ..
  68. MOLECULAR RECOGNITION OF HIV1 PRIMER TRNA LYS
    Karin Musier Forsyth; Fiscal Year: 2001
    b>Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that is the causative agent of AIDS. Human tRNALys,3, is selected as the natural primer for HIV-1 reverse transcriptase (RT)...
  69. ALVEOLAR MACROPHAGES AND DEFENSE OF THE LUNG IN AIDS
    Paul Luciw; Fiscal Year: 1993
    b>Human immunodeficiency virus type 1 (HIV-1), a lentivirus etiologically linked to AIDS and related disorders, infects principally CD4+ T- lymphocytes and cells in the monocyte/macrophage lineage...
  70. HIV-1 chemoprophylaxis and archived drug resistance in infants
    Deborah Persaud; Fiscal Year: 2010
    Nearly three million children worldwide have human immunodeficiency virus type 1 (HIV-1)/AIDS, and most live in sub-Saharan Africa where access to antiretroviral drugs is limited...
  71. ROLE OF ANTIVIRAL CTLS IN CONTROL OF HIV 1 IN MAN
    Persephone Borrow; Fiscal Year: 1999
    ..understanding of the role of virus-specific cytotoxic T lymphocytes (CTL) in virus control in human immunodeficiency virus type 1 (HIV-1)-infected individuals. HIV-1 is the causative agent of AIDS...
  72. Mechanism of HIV-1 attachment to dendritic cells
    Suryaram Gummuluru; Fiscal Year: 2010
    b>Human immunodeficiency virus type 1 (HIV-1) is the causative agent of AIDS in humans...
  73. CD8+ T CELL APOPTOSIS IN HIV INFECTION
    Georges Herbein; Fiscal Year: 2000
    CD8+ T lymphocytes play an important role in the control of human immunodeficiency virus type 1 (HIV) infection via HIV-specific cytotoxic T lymphocyte (CTL) activity and the release of soluble factors...

Patents62

  1. PRIME-BOOST REGIMENS WITH A TLR4 AGONIST ADJUVANT AND A LENTIVIRAL VECTOR
    Patent Number: WO2016011083-A1; Date:2016-01-21
  2. Mitochondrial Proteins Constructs and Uses Thereof
    Patent Number: JP2016520557-A; Date:2016-07-14
  3. RNA amplification and iagnostic method of HIV-1 infection
    Patent Number: JP2016063797-A; Date:2016-04-28
  4. Conditionally Immortalized Long-Term Stem Cells and Methods of Making and Using Such Cells
    Patent Number: JP2016129515-A; Date:2016-07-21
  5. A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW& AND HIGH MOLECULAR WEIGHT COMPOUNDS
    Patent Number: EP3001990-A1; Date:2016-04-06
  6. METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION
    Patent Number: KR1020160060659-A; Date:2016-05-30
  7. Genome editing for the treatment of huntington's disease
    Patent Number: EP2982758-A1; Date:2016-02-10
  8. PATHOGENIC CONTROL OF APOPTOSIS
    Patent Number: WO2016024257-A1; Date:2016-02-18
  9. Well-tolerated and highly specific tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains
    Patent Number: EP2993229-A1; Date:2016-03-09
  10. METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION
    Patent Number: EP3038661-A1; Date:2016-07-06
  11. METHODS FOR IDENTIFYING ANTIRETROVIRAL COMPOUNDS TARGETING THE REVERSE TRANSCRIPTASE OF HIV
    Patent Number: WO2016173715-A1; Date:2016-11-03
  12. METHODS FOR IDENTIFYING ANTIRETROVIRAL COMPOUNDS TARGETING THE REVERSE TRANSCRIPTASE OF HIV
    Patent Number: EP3088535-A1; Date:2016-11-02
  13. CAS 9 RETROVIRAL INTEGRASE AND CAS 9 RECOMBINASE SYSTEMS FOR TARGETED INCORPORATION OF A DNA SEQUENCE INTO A GENOME OF A CELL OR ORGANISM
    Patent Number: WO2016161207-A1; Date:2016-10-06
  14. WELL-TOLERATED AND HIGHLY SPECIFIC TAILORED RECOMBINASE FOR RECOMBINING ASYMMETRIC TARGET SITES IN A PLURALITY OF RETROVIRUS STRAINS
    Patent Number: WO2016034553-A1; Date:2016-03-10
  15. VSV-HIV viral particles lacking reverse transcriptase functionality and therapeutic applications thereof
    Patent Number: EP2703482-A1; Date:2014-03-05
  16. VSV-HIV VIRAL PARTICLES LACKING REVERSE TRANSCRIPTASE FUNCTIONALITY AND THERAPEUTIC APPLICATIONS THEREOF
    Patent Number: WO2014037409-A1; Date:2014-03-13
  17. MITOCHONDRIAL PROTEINS CONSTRUCTS AND USES THEREOF
    Patent Number: WO2014170896-A2; Date:2014-10-23
  18. COMPOUNDS THAT BIND TO HUMAN IMMUNODEFICIENCY VIRUS REV RESPONSE ELEMENT
    Patent Number: WO2015061573-A1; Date:2015-04-30
  19. IMMUNOTHERAPY OF CANCER THROUGH COMBINATION OF LOCAL AND SYSTEMIC IMMUNE STIMULATION
    Patent Number: WO2015123496-A1; Date:2015-08-20
  20. LENTIVIRAL VECTOR PARTICLES HAVING IMPROVED TRANSDUCTION EFFICIENCY FOR CELLS EXPRESSING DC-SIGN
    Patent Number: KR1020150014440-A; Date:2015-02-06
  21. VACCINES FOR HSV-2
    Patent Number: KR1020150014500-A; Date:2015-02-06
  22. STABILIZED GP120
    Patent Number: KR1020150023735-A; Date:2015-03-05
  23. CYCLOPENTANE-PEPTIDE NUCLEIC ACIDS FOR QUALITATIVE AND QUANTITATIVE DETECTION OF NUCLEIC ACIDS
    Patent Number: KR1020150041657-A; Date:2015-04-16
  24. Pharmaceutical composition for autosomal dominant polycystic kidney disease containing PRAS40 fusion protein
    Patent Number: KR1020150101098-A; Date:2015-09-03
  25. Pharmaceutical composition for treating ischemia containing cell-transducible PRAS40 fusion protein
    Patent Number: KR1020150106985-A; Date:2015-09-23
  26. MITOCHONDRIAL PROTEINS CONSTRUCTS AND USES THEREOF
    Patent Number: KR1020150143778-A; Date:2015-12-23
  27. HIV-1 DETECTION
    Patent Number: WO2014037712-A2; Date:2014-03-13
  28. METHODS FOR ENHANCING IMMUNOGEN SPECIFIC IMMUNE RESPONSES BY VECTORED VACCINES
    Patent Number: JP2014510721-A; Date:2014-05-01
  29. IMMUNOGENIC COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR INDUCING HUMORAL AND CELLULAR IMMUNE RESPONSES
    Patent Number: JP2014516355-A; Date:2014-07-10
  30. METHODS FOR IMPROVING AND MANAGING NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITION BASED TREATMENT
    Patent Number: JP2014519321-A; Date:2014-08-14
  31. POLYVALENT VACCINE
    Patent Number: JP2014207910-A; Date:2014-11-06
  32. USE OF NON-SUBTYPE B GAG PROTEINS FOR LENTIVIRAL PACKAGING
    Patent Number: JP2014530000-A; Date:2014-11-17
  33. SIGNAL ENCODING AND DECODING IN MULTIPLEXED BIOCHEMICAL ASSAYS
    Patent Number: JP2015508642-A; Date:2015-03-23
  34. ATTENUATED VIRUSES USEFUL FOR VACCINES
    Patent Number: JP2015091247-A; Date:2015-05-14
  35. Lentiviral Vectors Pseudotyped with a Sindbis Virus Envelope Glycoprotein
    Patent Number: JP2015109853-A; Date:2015-06-18
  36. LENTIVIRAL VECTOR PARTICLES HAVING IMPROVED TRANSDUCTION EFFICIENCY FOR CELLS EXPRESSING DC-SIGN
    Patent Number: JP2015512263-A; Date:2015-04-27
  37. Vaccines for HSV-2
    Patent Number: JP2015522540-A; Date:2015-08-06
  38. Conditionally Immortalized Long-Term Stem Cells and Methods of Making and Using Such Cells
    Patent Number: JP2014158503-A; Date:2014-09-04
  39. Pharmaceutical composition for treating skin inflammation containing Biliverdin reductase A fusion protein
    Patent Number: KR1020150055246-A; Date:2015-05-21
  40. SIGNAL ENCODING AND DECODING IN MULTIPLEXED BIOCHEMICAL ASSAYS
    Patent Number: KR1020140127282-A; Date:2014-11-03
  41. USE OF NON-SUBTYPE B GAG PROTEINS FOR LENTIVIRAL PACKAGING
    Patent Number: KR1020140116053-A; Date:2014-10-01
  42. N-TERMINAL DELETED GP120 IMMUNOGENS
    Patent Number: EP2739300-A2; Date:2014-06-11
  43. Non-integrating lentiviral vectors
    Patent Number: EP2770061-A1; Date:2014-08-27
  44. DETECTION OF NUCLEIC ACIDS USING UNMODIFIED GOLD NANOPARTICLES
    Patent Number: EP2694685-A1; Date:2014-02-12
  45. A means of producing and utilising a population of disease specific cytotoxic T lymphocytes
    Patent Number: JP2006505259-A; Date:2006-02-16
  46. Immunoassay method and reagent for hiv-1p24 antigen
    Patent Number: EP1072888-A2; Date:2001-01-31
  47. INHIBITION OF HIV-1 REPLICATION BY DISRUPTION OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN
    Patent Number: JP2006520756-A; Date:2006-09-14
  48. A method for producing a virus protease
    Patent Number: JP2009124993-A; Date:2009-06-11
  49. Synthetic antigen for the detection of antibodies immunoreactive with HIV virus
    Patent Number: EP1878805-A; Date:2008-01-16
  50. Methods for the in vitro screening of compounds inhibiting production of infectious hiv-1 virions and compounds selected by said method
    Patent Number: WO2007128806-A; Date:2007-11-15
  51. Nucleotide sequence for detection and characterization of the hiv-1 field isolates participating in the recombination processes directed by the chi sequence
    Patent Number: EP1043407-A2; Date:2000-10-11
  52. Methods and compostions relating to the pharmacogenetics of different gene variants in the context of irinotecan-based therapies
    Patent Number: WO2006124646-A2; Date:2006-11-23
  53. HIV-1 VACCINES AND SCREENING METHODS THEREFOR
    Patent Number: JP2004520262-A; Date:2004-07-08
  54. Hiv tev compositions and methods of use
    Patent Number: WO2007098257-A2; Date:2007-08-30
  55. Tat-based immunomodulatory compositions and methods of their discovery and use
    Patent Number: WO2005090968-A1; Date:2005-09-29
  56. Tat-based tolerogen compositions and methods of making and using same
    Patent Number: WO2005090392-A1; Date:2005-09-29
  57. A1 MOIETY OF CHOLERA TOXIN A SUBUNIT AS AN ADJUVANT FOR MUCOSAL AND SYSTEMIC VACCINES
    Patent Number: EP2350132-A2; Date:2011-08-03
  58. PLASMID HAVING THREE COMPLETE TRANSCRIPTIONAL UNITS AND IMMUNOGENIC COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE TO HIV
    Patent Number: JP2011115178-A; Date:2011-06-16
  59. Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates
    Patent Number: EP0570357-A2; Date:1993-11-18
  60. Immunogen platform
    Patent Number: WO2009130588-A2; Date:2009-10-29
  61. SELECTION OF TARGET-SPECIFIC ZINC FINGER DOMAINS
    Patent Number: JP2003523195-A; Date:2003-08-05
  62. Vpr modulation and uses thereof
    Patent Number: WO03076621-A2; Date:2003-09-18